CRIS Current Research Information System

DERENZINI, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.145
AS - Asia 3.390
EU - Europa 2.762
AF - Africa 181
SA - Sud America 163
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.651
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.095
VN - Vietnam 1.025
SG - Singapore 949
CN - Cina 780
GB - Regno Unito 695
SE - Svezia 485
DE - Germania 365
IT - Italia 297
HK - Hong Kong 230
IN - India 172
FR - Francia 162
RU - Federazione Russa 146
BR - Brasile 106
IE - Irlanda 100
UA - Ucraina 93
NL - Olanda 82
CH - Svizzera 79
ZA - Sudafrica 65
EE - Estonia 61
FI - Finlandia 59
JP - Giappone 56
TG - Togo 47
CA - Canada 31
PL - Polonia 28
BG - Bulgaria 25
CI - Costa d'Avorio 24
BD - Bangladesh 23
PH - Filippine 20
HR - Croazia 19
KR - Corea 19
NG - Nigeria 18
AR - Argentina 16
BE - Belgio 16
IQ - Iraq 13
IR - Iran 13
ES - Italia 11
ID - Indonesia 11
JO - Giordania 11
MX - Messico 11
TH - Thailandia 11
GR - Grecia 10
CL - Cile 9
AT - Austria 8
EC - Ecuador 8
LB - Libano 7
TR - Turchia 7
TW - Taiwan 7
LT - Lituania 6
PY - Paraguay 6
SC - Seychelles 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
MY - Malesia 5
PE - Perù 5
VE - Venezuela 5
AU - Australia 4
CO - Colombia 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
ET - Etiopia 4
KE - Kenya 4
PK - Pakistan 4
SA - Arabia Saudita 4
BO - Bolivia 3
HU - Ungheria 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
TN - Tunisia 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
GE - Georgia 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BY - Bielorussia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EU - Europa 1
GH - Ghana 1
GT - Guatemala 1
HT - Haiti 1
IL - Israele 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
OM - Oman 1
PR - Porto Rico 1
TM - Turkmenistan 1
UY - Uruguay 1
Totale 10.651
Salva come PNG Salva come JPEG
Città #
Singapore 635
Southend 605
Fairfield 448
Ashburn 427
Chandler 344
Dong Ket 310
Woodbridge 228
Houston 222
Hong Kong 213
Wilmington 203
Seattle 191
Ann Arbor 173
Santa Clara 163
Ho Chi Minh City 150
San Jose 150
Princeton 141
Cambridge 133
Hanoi 128
Beijing 121
Dublin 100
Boardman 96
Bern 75
Nanjing 73
Westminster 63
Padova 60
Lauterbourg 56
New York 54
Helsinki 53
Los Angeles 52
Tokyo 48
Lomé 47
Jacksonville 45
Berlin 43
Bologna 41
Jinan 40
Hefei 36
Changsha 35
Dallas 35
Frankfurt am Main 32
San Diego 32
Shenyang 28
Florence 27
Saint Petersburg 27
Hebei 26
Bremen 25
Abidjan 24
Buffalo 24
Sofia 24
Council Bluffs 22
Haiphong 22
Redondo Beach 22
Hyderabad 21
Milan 21
Turin 21
Warsaw 21
Redwood City 19
Toronto 19
São Paulo 18
Jiaxing 17
Medford 17
Munich 17
Abeokuta 16
London 16
Brussels 15
Chicago 15
Da Nang 15
Dearborn 15
Guangzhou 15
Ningbo 15
Norwalk 15
Shanghai 15
Phoenix 14
Zhengzhou 14
Mülheim 13
Nanchang 13
Redmond 13
Hangzhou 12
Seoul 12
Taizhou 12
Amman 11
Biên Hòa 10
Falkenstein 10
Haikou 9
San Francisco 9
Tianjin 9
Can Tho 8
Falls Church 8
Mountain View 8
Olalla 8
Taiyuan 8
Jakarta 7
Lanzhou 7
Yubileyny 7
Amsterdam 6
Bangkok 6
Des Moines 6
Dhaka 6
Düsseldorf 6
Fuzhou 6
Monmouth Junction 6
Totale 6.979
Salva come PNG Salva come JPEG
Nome #
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 261
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 254
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 251
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 237
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 235
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 232
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 221
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 217
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 216
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 215
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 214
RALE051: a novel established cell line of sporadic Burkitt lymphoma 209
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 209
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 207
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 207
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 201
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 201
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 199
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 196
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 193
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 191
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 188
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 185
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 184
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 182
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 181
Treatment of colorectal cancer liver metastases 180
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 173
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 171
Bendamustine: role and evidence in lymphoma therapy, an overview. 167
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 167
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 164
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. 163
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 162
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 162
Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. 159
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 159
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 158
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 154
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 153
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 150
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia 148
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. 148
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 147
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 145
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 144
Clinical safety and efficacy of adjuvant chemotherapy in radically resected cholangiocarcinoma patients. 139
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 137
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. 134
The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma 133
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. 126
Systemic adjuvant chemotherapy after resection of colorectal cancer metastases 126
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. 126
SINGLE-AGENT INHIBITION OF CHECKPOINT KINASE 1 (CHK1) AND 2 (CHK2) BY PF-0477736 (PFIZER) AS A NEW PROMISING THERAPY IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 125
GEMOX AS FIRST-LINE CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER (APC): A MONOISTITUTIONAL EXPERIENCE. 122
IMPACT OF MULTIDISCIPLINARY APPROACH ON SURVIVAL OF PATIENTS WITH KLATSKIN TUMOR 121
Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease. 115
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 108
The tratment of liver metastases from colorectal cancer: questions more than answers? 104
Phase I/II trial of continuous hepatic arterial infusion (HAI) of Irinotecan in patients with hepatocellular carcinoma (HCC). Preliminary results 96
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 88
METRONOMIC CAPECITABINE IN ADVANCED PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): PRELIMINARY RESULTS. 88
Liver metastases from colorectal cancer 87
Phase I/II trial of continuous hepatic arterial infusion (HAI) of irinotecan in patients with hepatocellular carcinoma (HCC). 82
null 75
Gemcitabine 25
Totale 10.817
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.124
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.124
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021553 0 0 0 0 0 0 0 0 0 34 52 467
2021/20221.385 196 53 104 144 108 71 45 71 48 89 245 211
2022/20231.484 197 200 83 189 96 120 29 80 196 47 113 134
2023/2024356 28 62 13 44 22 90 19 14 9 27 6 22
2024/20251.338 40 208 106 91 248 40 117 36 14 128 33 277
2025/20262.639 182 183 250 170 355 195 303 112 677 212 0 0
Totale 10.817